Related references
Note: Only part of the references are listed.Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis A Randomized, Phase 3, Clinical Trial
Patrick Vermersch et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)
Decoding Mast Cell-Microglia Communication in Neurodegenerative Diseases
Jagdeep K. Sandhu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Fangda Leng et al.
NATURE REVIEWS NEUROLOGY (2021)
The Role of Microglia in Sporadic Alzheimer's Disease
Wolfgang J. Streit et al.
JOURNAL OF ALZHEIMERS DISEASE (2021)
Alzheimer's disease
Philip Scheltens et al.
LANCET (2021)
Dystrophic microglia are associated with neurodegenerative disease and not healthy aging in the human brain
Ryan K. Shahidehpour et al.
NEUROBIOLOGY OF AGING (2021)
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial
Jesus S. Mora et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2020)
Effects of Chronic Masitinib Treatment in APPswe/PSEN1dE9 Transgenic Mice Modeling Alzheimer's Disease
Tengfei Li et al.
JOURNAL OF ALZHEIMERS DISEASE (2020)
Shifting paradigms: The central role of microglia in Alzheimer's disease
Tina Schwabe et al.
NEUROBIOLOGY OF DISEASE (2020)
Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer's Disease
You Jung Kang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
Hyuk Sung Kwon et al.
TRANSLATIONAL NEURODEGENERATION (2020)
Glial activation and inflammation along the Alzheimer's disease continuum
Kaja Nordengen et al.
JOURNAL OF NEUROINFLAMMATION (2019)
Mast Cells in Stress, Pain, Blood-Brain Barrier, Neuroinflammation and Alzheimer's Disease
Duraisamy Kempuraj et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2019)
Mast Cells in Neurodegenerative Disease
Michael K. Jones et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2019)
Innate Immune Cells: Monocytes, Monocyte-Derived Macrophages and Microglia as Therapeutic Targets for Alzheimer's Disease and Multiple Sclerosis
Adham Fani Maleki et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2019)
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Justin M. Long et al.
CELL (2019)
Microglia in Alzheimer's disease
David V. Hansen et al.
JOURNAL OF CELL BIOLOGY (2018)
An Inflammation-Centric View of Neurological Disease: Beyond the Neuron
Stephen D. Skaper et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2018)
Microglial priming in Alzheimer's disease
Jun-Wei Li et al.
ANNALS OF TRANSLATIONAL MEDICINE (2018)
Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS
Emiliano Trias et al.
JCI INSIGHT (2018)
Neuroimmune Activation Drives Multiple Brain States
Daria Tchessalova et al.
FRONTIERS IN SYSTEMS NEUROSCIENCE (2018)
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Clifford R. Jack et al.
NEUROLOGY (2016)
Masitinib for the treatment of mild to moderate Alzheimer's disease
Jaume Folch et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch
Jose L. Molinuevo et al.
ALZHEIMERS RESEARCH & THERAPY (2015)
Masitinib for the treatment of mild to moderate Alzheimer's disease
Jaume Folch et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Does the evidence say a 4-point change in ADAS-cog score is clinically significant?
Mark Oremus
ALZHEIMERS & DEMENTIA (2014)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois et al.
LANCET NEUROLOGY (2014)
Alzheimer's disease drug-development pipeline: few candidates, frequent failures
Jeffrey L. Cummings et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
Eric Karran et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
Francois Piette et al.
ALZHEIMERS RESEARCH & THERAPY (2011)
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
Patrice Dubreuil et al.
PLOS ONE (2009)
Imputation strategies for missing continuous outcomes in cluster randomized trials
Monica Taljaard et al.
BIOMETRICAL JOURNAL (2008)
Endpoints for trials in Alzheimer's disease: a European task force consensus
Bruno Vellas et al.
LANCET NEUROLOGY (2008)
The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial
Kenneth Rockwood et al.
BMC NEUROLOGY (2007)
Share Paper
